INVESTALGA AHTI S.L.

investalga.com

INVESTALGA is a Spanish innovative biotech specializing in the production of high quality bioactive compounds from green seaweeds available for use in nutrition, personal care and health markets. We are developing a scientific-technical-industrial base combining various disciplines: biotechnology, marine ecology, aquaculture, chemistry, nutrition and medicine, to credit and put value to the numerous possibilities derived from the unique biochemical composition of green seaweeds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

news image

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

news image

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

news image

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

news image

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More
news image

Medical

SOPHIA GENETICS LAUNCHES NEW SOLUTION TO ADVANCE CHRONIC LYMPHOCYTIC LEUKEMIA CARE, IN COLLABORATION WITH IDIBAPS

biotech, biotechnology, cell, gene, tissue | June 10, 2022

SOPHiA GENETICS (Nasdaq: SOPH), the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) of Barcelona, and the Spanish Diagnóstica Longwood today announced from the European Hematology Association Congress in Vienna that they have combined their expertise to develop a new Chronic Lymphocytic Leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into one single application aiming to improve ...

Read More
news image

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More
news image

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More
news image

Industrial Impact

LARONDE ATTRACTS $440M IN FIRST EXTERNAL FINANCING TO FURTHER ADVANCE ENDLESS RNA™ PLATFORM

Laronde | August 30, 2021

Laronde, the company pioneering Endless RNA™ a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body, today announced that it has raised $440 Million in a Series B Financing to advance the development of its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The financing round included the company's founder, Flagship Pioneering, along with funds and accounts advised by T. Rowe Price Associates, Inc.,...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

Characterization and identification of glucuronide metabolites

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Single-cell RNA Sequencing and Analysis

Video

resource image

Cell and Gene Therapy, Industrial Impact

Characterization and identification of glucuronide metabolites

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us